Collateral sensitivity: An evolutionary trade-off between antibiotic resistance mechanisms, attractive for dealing with drug-resistance crisis.
antimicrobial agents
collateral sensitivity
combination therapy
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
12
04
2023
revised:
29
06
2023
accepted:
29
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
The discovery and development of antimicrobial drugs were one of the most significant advances in medicine, but the evolution of microbial resistance limited the efficiency of these drugs. This paper reviews the collateral sensitivity in bacteria and its potential and limitation as a new target for treating infections. Knowledge mechanisms of resistance to antimicrobial agents are useful to trace a practical approach to treat and control of resistant pathogens. The effect of a resistance mechanism to certain antibiotics on the susceptibility or resistance to other drugs is a key point that may be helpful for applying a strategy to control resistance challenges. In an evolutionary trade-off known as collateral sensitivity, the resistance mechanism to a certain drug may be mediated by the hypersensitivity to other drugs. Collateral sensitivity has been described for different drugs in various bacteria, but the molecular mechanisms affecting susceptibility are not well demonstrated. Collateral sensitivity could be studied to detect its potential in the battle against resistance crisis as well as in the treatment of pathogens adapting to antibiotics. Collateral sensitivity-based antimicrobial therapy may have the potential to limit the emergence of antibiotic resistance.
Sections du résumé
Background
UNASSIGNED
The discovery and development of antimicrobial drugs were one of the most significant advances in medicine, but the evolution of microbial resistance limited the efficiency of these drugs.
Aim
UNASSIGNED
This paper reviews the collateral sensitivity in bacteria and its potential and limitation as a new target for treating infections.
Results and Discussion
UNASSIGNED
Knowledge mechanisms of resistance to antimicrobial agents are useful to trace a practical approach to treat and control of resistant pathogens. The effect of a resistance mechanism to certain antibiotics on the susceptibility or resistance to other drugs is a key point that may be helpful for applying a strategy to control resistance challenges. In an evolutionary trade-off known as collateral sensitivity, the resistance mechanism to a certain drug may be mediated by the hypersensitivity to other drugs. Collateral sensitivity has been described for different drugs in various bacteria, but the molecular mechanisms affecting susceptibility are not well demonstrated. Collateral sensitivity could be studied to detect its potential in the battle against resistance crisis as well as in the treatment of pathogens adapting to antibiotics. Collateral sensitivity-based antimicrobial therapy may have the potential to limit the emergence of antibiotic resistance.
Identifiants
pubmed: 37448730
doi: 10.1002/hsr2.1418
pii: HSR21418
pmc: PMC10336338
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1418Informations de copyright
© 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Biol Chem. 2001 Nov 16;276(46):43111-21
pubmed: 11535603
Burns. 2005 Nov;31(7):870-3
pubmed: 15975720
Int J Med Microbiol. 2013 Aug;303(6-7):287-92
pubmed: 23499305
J Bacteriol. 2008 Sep;190(18):6253-7
pubmed: 18621902
Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4495-4500
pubmed: 28396391
Science. 2016 Jan 1;351(6268):aad3292
pubmed: 26722002
Mol Syst Biol. 2013 Oct 29;9:700
pubmed: 24169403
PLoS Biol. 2020 Jan 27;18(1):e3000612
pubmed: 31986134
GMS Hyg Infect Control. 2017 Aug 17;12:Doc13
pubmed: 28840093
J Biol Chem. 2001 Nov 16;276(46):43132-44
pubmed: 11535605
ChemMedChem. 2019 Aug 20;14(16):1560-1572
pubmed: 31283109
Sci Adv. 2020 Aug 05;6(32):eaba5493
pubmed: 32821825
Mol Biol Evol. 2017 Sep 1;34(9):2229-2244
pubmed: 28541480
Infect Genet Evol. 2017 Sep;53:189-194
pubmed: 28600216
Iran J Pharm Res. 2021 Spring;20(2):286-296
pubmed: 34567162
Evol Appl. 2015 Mar;8(3):273-83
pubmed: 25861385
J Antimicrob Chemother. 2010 Sep;65(9):2037-40
pubmed: 20587611
Front Microbiol. 2017 Dec 05;8:2303
pubmed: 29259579
Nat Commun. 2019 Jan 18;10(1):334
pubmed: 30659188
Nat Commun. 2014 Jul 08;5:4352
pubmed: 25000950
Res Microbiol. 2021 Mar;172(2):103798
pubmed: 33485914
PLoS Biol. 2019 Oct 25;17(10):e3000515
pubmed: 31652256
Antimicrob Agents Chemother. 2000 Dec;44(12):3322-7
pubmed: 11083635
J Glob Antimicrob Resist. 2019 Jun;17:39-43
pubmed: 30445211
Microb Pathog. 2020 Dec;149:104506
pubmed: 32950639
Antimicrob Agents Chemother. 2015 Nov;59(11):6733-40
pubmed: 26282415
Crit Rev Microbiol. 2004;30(1):25-32
pubmed: 15116761
Wiley Interdiscip Rev Syst Biol Med. 2016 May;8(3):253-67
pubmed: 27103502
Tuberculosis (Edinb). 2013 Mar;93(2):150-4
pubmed: 23276692
J Toxicol Pathol. 2018 Jul;31(3):179-188
pubmed: 30093787
J Bacteriol. 1996 Sep;178(17):5092-9
pubmed: 8752324
Annu Rev Biophys. 2013;42:493-514
pubmed: 23654305
Nat Rev Microbiol. 2015 Jan;13(1):42-51
pubmed: 25435309
Trends Microbiol. 2015 Jul;23(7):401-7
pubmed: 25818802
GMS Hyg Infect Control. 2017 Oct 17;12:Doc17
pubmed: 29094001
J Antimicrob Chemother. 2005 Jan;55(1):6-9
pubmed: 15531594
Life Sci. 2020 Dec 1;262:118562
pubmed: 33038378
Antimicrob Agents Chemother. 2010 Dec;54(12):4971-7
pubmed: 20855724
AAPS J. 2015 May;17(3):513-24
pubmed: 25700799
Antimicrob Agents Chemother. 1989 Sep;33(9):1549-52
pubmed: 2684011
Antimicrob Agents Chemother. 2008 Jul;52(7):2455-62
pubmed: 18474583
Water Res. 2014 Jan 1;48:100-7
pubmed: 24091187
Gut. 2011 Sep;60(9):1269-77
pubmed: 21292683
Cold Spring Harb Perspect Med. 2016 Jun 01;6(6):
pubmed: 27252397
Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60
pubmed: 21859938
Cold Spring Harb Perspect Med. 2016 Jul 01;6(7):
pubmed: 27235477
Microb Biotechnol. 2022 Feb;15(2):613-629
pubmed: 33960651
Diagn Microbiol Infect Dis. 2007 Oct;59(2):211-6
pubmed: 17521840
Microbiology (Reading). 2000 Oct;146 ( Pt 10):2543-2554
pubmed: 11021929
Ups J Med Sci. 2014 May;119(2):103-7
pubmed: 24694026
Nat Genet. 2015 Jan;47(1):57-64
pubmed: 25401299
EMBO Mol Med. 2014 Mar;6(3):372-83
pubmed: 24500695
PLoS Biol. 2013 Oct;11(10):e1001692
pubmed: 24204207
ACS Appl Mater Interfaces. 2017 May 3;9(17):15022-15030
pubmed: 28393523
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28607015
PLoS Pathog. 2013;9(11):e1003711
pubmed: 24244154
J Antimicrob Chemother. 2018 Jun 1;73(6):1525-1529
pubmed: 29566151
BMC Microbiol. 2015 Oct 19;15:218
pubmed: 26482905
Malar J. 2018 Mar 13;17(1):110
pubmed: 29534720
Mol Biol Evol. 2014 Sep;31(9):2387-401
pubmed: 24962091
Trans R Soc Trop Med Hyg. 2020 Oct 5;114(10):770-781
pubmed: 32609840
Microbiol Mol Biol Rev. 2010 Sep;74(3):417-33
pubmed: 20805405
Acta Microbiol Immunol Hung. 2019 Dec 1;66(4):529-540
pubmed: 31707785
Int J Antimicrob Agents. 2015 Dec;46(6):696-702
pubmed: 26391380
Clin Pharmacokinet. 2017 Dec;56(12):1441-1460
pubmed: 28550595
Nat Rev Microbiol. 2011 Nov 02;9(12):894-6
pubmed: 22048738
Clin Microbiol Rev. 2012 Jul;25(3):450-70
pubmed: 22763634
Int J Med Microbiol. 2017 Dec;307(8):452-459
pubmed: 28986014
Infect Genet Evol. 2018 Oct;64:156-163
pubmed: 29936037
Curr Opin Pharmacol. 2011 Oct;11(5):477-85
pubmed: 21840259
Sci Transl Med. 2014 Nov 12;6(262):262ra156
pubmed: 25391482
Infect Drug Resist. 2018 Apr 24;11:567-576
pubmed: 29731645
Antimicrob Agents Chemother. 2013 Nov;57(11):5521-6
pubmed: 23979739
Sci Transl Med. 2013 Sep 25;5(204):204ra132
pubmed: 24068739
Cell. 2018 Jan 11;172(1-2):121-134.e14
pubmed: 29307490
Antimicrob Agents Chemother. 2019 Dec 20;64(1):
pubmed: 31611347
Antimicrob Agents Chemother. 2016 Jul 22;60(8):5076-9
pubmed: 27270288
Cell. 2000 Sep 29;103(1):113-25
pubmed: 11051552
Microb Drug Resist. 2020 Jan;26(1):1-8
pubmed: 31393205
Nat Rev Microbiol. 2014 Jul;12(7):465-78
pubmed: 24861036
Nature. 2018 Sep;561(7724):479-484
pubmed: 30258136
Front Cell Infect Microbiol. 2017 Jun 16;7:246
pubmed: 28670570
Evol Med Public Health. 2019 Feb 22;2019(1):37-45
pubmed: 30906555
Phys Rev Lett. 2011 May 13;106(19):198102
pubmed: 21668204
Annu Rev Biochem. 2015;84:577-601
pubmed: 26034890
Ann Intern Med. 2016 Sep 6;165(5):363-72
pubmed: 27239977
Cell Chem Biol. 2019 Oct 17;26(10):1355-1364.e4
pubmed: 31402316
BMC Public Health. 2019 Jul 02;19(1):858
pubmed: 31266477
Expert Rev Anti Infect Ther. 2020 Jan;18(1):5-15
pubmed: 31847614
Mol Microbiol. 2001 Apr;40(2):433-9
pubmed: 11309125
Future Microbiol. 2012 Aug;7(8):959-78
pubmed: 22913355
Nat Rev Genet. 2008 Nov;9(11):855-67
pubmed: 18852697